On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK).
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The stock advanced 1.62% to close the day at $75.28 with a total volume of 5.43 million shares traded. The Company’s shares have gained 3.09% in the last one month and 14.54% in the past three months. Furthermore, the Company’s stock has advanced 13.46% in the previous one year. The stock is trading 5.14% and 14.31% above its 50-day and 200-day moving averages, respectively. Additionally, Bristol-Myers Squibb’s stock traded at a PE ratio of 80.43 and has a Relative Strength Index (RSI) of 66.42.
On Friday, shares in AstraZeneca PLC which engages in the discovery, development, and commercialization of prescription medicines for the treatment of respiratory, inflammation, autoimmune, cardiovascular, metabolic, oncology, infection, neuroscience, and gastrointestinal diseases worldwide, ended the session flat at $30.11 with a total volume of 3.78 million shares traded. Shares of the Company traded at a PE ratio of 26.07. The Company’s shares have advanced 1.59% in the last one month, and 2.24% in the previous three months. The stock is trading 3.98% above its 50-day moving average. Moreover, shares of AstraZeneca have an RSI of 60.15.
On Friday, shares in Eli Lilly and Co. which discovers, develops, manufactures, and markets pharmaceutical products worldwide, ended the day 0.43% higher at $79.66 with a total volume of 3.13 million shares traded. Shares of the Company traded at a PE ratio of 36.56. The Company’s shares have advanced 6.34% in the last one month and 7.80% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 5.59% and 2.83%, respectively. Furthermore, shares of Eli Lilly have an RSI of 69.17.
GlaxoSmithKline PLC’s stock finished Friday’s session 0.09% higher at $43.38 with a total volume of 2.17 million shares traded. Over the last one month and the previous three months, the Company’s shares have advanced 2.05% and 5.77%, respectively. The stock is trading above its 50-day and 200-day moving averages by 3.01% and 9.10%, respectively. GlaxoSmithKline’s stock traded at a PE ratio of 133.89 and has an RSI of 58.76. The Company was founded in 1935 and is headquartered in Brentford, the U.K.